Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01247220 · ClinicalTrials.gov registry record · Phase 2
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
A Phase 2 study of Macular Edema and Branch Retinal Vein Occlusion, sponsored by Retina Associates of Florida, P.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01247220 is a Phase 2 study of Macular Edema and Branch Retinal Vein Occlusion that has completed, run by Retina Associates of Florida, P.A.. The registered enrollment target is 12 participants, below the 179-participant average among 14 other Macular Edema trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01247220, a Phase 2 study of Macular Edema and Branch Retinal Vein Occlusion, has completed, sponsored by Retina Associates of Florida, P.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results. There is a subgroup of patients with peripheral nonperfusion on ultrawidefield angiography that appears to be more dependent on anti-VEGF treatment. In this trial the investigators compare the gold standard of monthly ranibizumab injections with ranibizumab + peripheral scatter laser to the areas of nonperfusion on angiography. Each group will have monthly injections for the first six months, then as needed by either visual acuity decrease or increased retinal thickness for the subsequent six months. The primary outcome is visual acuity. Secondary outcomes are reduction in optical coherence tomography, and number of ranibizumab injections
Conditions Studied
Interventions
- DRUG Ranibizumab
- PROCEDURE Peripheral Laser
Study Locations (1)
Florida
- Retina Associates of Florida, P.A. - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01247220
The ClinicalTrials.gov registry entry for NCT01247220 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 14 other Macular Edema trials with a reported enrollment target (93% lower). The listed sponsor is Retina Associates of Florida, P.A., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab is the first listed.
NCT01247220 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01247220 about?
NCT01247220 is a clinical study titled "REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study". Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results. There is a subgroup of patients with peripheral nonperfusion on ultrawidefield angiog...
What is the current status of trial NCT01247220?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2010-11. Estimated completion is 2014-05.
What conditions does trial NCT01247220 study?
This clinical trial studies the following conditions: Macular Edema, Branch Retinal Vein Occlusion.
What interventions are being tested in trial NCT01247220?
The interventions under investigation include: Ranibizumab (DRUG), Peripheral Laser (PROCEDURE).
Who is sponsoring clinical trial NCT01247220?
This trial is sponsored by Retina Associates of Florida, P.A., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01247220 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
RECRUITING · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
COMPLETED · Phase 2
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
COMPLETED · Phase 3
-
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.